Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc (USA)  

(Public, NASDAQ:MSLI)   Watch this stock  
Find more results for MSLI
1.43
+0.05 (3.62%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.41 - 1.46
52 week 0.46 - 2.15
Open 1.41
Vol / Avg. 4,029.00/9,856.00
Mkt cap 74.25M
P/E     -
Div/yield     -
EPS -0.06
Shares 51.92M
Beta 0.80
Inst. own 1%
Feb 14, 2014
Q1 2014 Envoy Capital Group Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2013
Net profit margin 16.01% -6.09%
Operating margin 38.58% 25.07%
EBITD margin - 64.72%
Return on average assets 5.83% -1.93%
Return on average equity 12.44% -4.37%
Employees 6 -
CDP Score - -

Address

Suite 2110 100 Wellington St. West P.O. Box 151
TORONTO, ON M5K 1H1
Canada
+1-416-5933725 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Merus Labs International Inc. (Merus), formerly Envoy Capital Group Inc., is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. It has products in the area of urology/women's health, anti-infective, and wound care. Its products include Factive, Emselex/Enable, Vancocin and Collacare and Collexa. On January 6, 2012, the Company acquired 51% of Orbis Pharma Inc. On March 7, 2012, the Company completed the acquisition of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets from Cornerstone Therapeutics Inc. In August 2013, the Company announced that the divestiture of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets to Okana Ventures Inc.

Officers and directors

David D. Guebert CPA Independent Chairman of the Board
Bio & Compensation  - Reuters
Elie Farah President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Ahmad Doroudian Executive Vice Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Andrew Patient Chief Financial Officer
Bio & Compensation  - Reuters
Ulrich Schoeberl Managing Director, European Operations
Bio & Compensation  - Reuters
Robert S. Pollock Independent Director
Bio & Compensation  - Reuters
Timothy G. Sorensen Independent Director
Bio & Compensation  - Reuters
Michael S. Cloutier Non-Executive Independent Director
Bio & Compensation  - Reuters